ÀÌ¿ø±â ±³¼ö, ´ëÇѳ²¼º°úÇÐȸ¼­ Çмú»ó ¼ö»ó
2014³â 04¿ù 15ÀÏ 08½Ã 54ºÐ ÀÔ·Â

±â»ç ³»¿ë »ðÀÔ À̹ÌÁö
[¿Óóµ¥Àϸ®] ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ºñ´¢±â°ú ÀÌ¿ø±â ±³¼ö°¡ Áö³­ 5ÀÏ ¼­¿ï»ï¼ºÀÇ·á¿ø¿¡¼­ ¿­¸° ¡®´ëÇѳ²¼º°úÇÐȸ Á¦31Â÷ Çмú´ëȸ ¹× ´ëÇÑ¿©¼º¼º°Ç°­¿¬±¸È¸ Á¦14Â÷ Çмú´ëȸ¡¯¿¡¼­ Çмú»óÀ» ¼ö»óÇß´Ù.


ÀÌ ±³¼ö´Â ¼ºÀÇÇÐ ºÐ¾ß¿¡¼­ ±¹Á¦ÀûÀ¸·Î °¡Àå ±ÇÀ§ÀÖ´Â Àú³ÎÀÎ ¡®Journal of Sexual Medicine¡¯¿¡ °ÔÀçÇÑ ¡®Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized double-blind, placebo-controlled multicenter study¡¯ ³í¹®ÀÇ ¿ì¼ö¼ºÀ» ÀÎÁ¤¹Þ¾Æ »óÀ» ¹Þ¾Ò´Ù.


ÀÌ ³í¹®Àº Ä¡·á¹æ¹ýÀÌ ¸¹Áö ¾ÊÀº Á¶·ç(premature ejaculation)¿¡ ´ëÇØ Æ÷½ºÆ÷µð¿¡½ºÆ®¶óÁ¦-5 ¾ïÁ¦Á¦ÀÇ Ä¡·á È¿°ú¸¦ ÀÓ»óÀûÀ¸·Î ÀÔÁõÇØ Á¶·ç Ä¡·áÀÇ ÆøÀ» ³ÐÇû´Ù´Â ÆòÀ» ¹Þ¾Ò´Ù.


Æ÷½ºÆ÷µð¿¡½ºÆ®¶óÁ¦-5 ¾ïÁ¦Á¦´Â ¹ß±âºÎÀüÀ̳ª Àü¸³¼± ºñ´ëÁõÀÇ Ä¡·áÁ¦·Î ÁÖ·Î »ç¿ëµÇ¾î ¿ÔÁö¸¸ FDA ½ÂÀÎÀ» ¹ÞÀº ´ÙÆø¼¼Æ¾°ú ÇÔ²² »ç¿ëÇßÀ» ¶§ Á¶·ç¿¡ ±àÁ¤ÀûÀÎ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ÀÌ¿ø±â ±³¼ö´Â Áö³­ 2011³â°ú 2013³â¿¡µµ ÀÌ Çмú´ëȸ¿¡¼­ ÃÖ¿ì¼ö ¹ßÇ¥»óÀ» ¹Þ¾Ò´Ù.


ÀÌ ±³¼ö´Â ÇöÀç ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ºñ´¢±â°ú °úÀåÀ¸·Î ±¹Á¦¼ºÀÇÇÐȸ Á¤È¸¿ø, ¾Æ½Ã¾ÆÅÂÆò¾ç ¼ºÀÇÇÐȸ °£ÇàÀ§¿ø, ¾Æ½Ã¾Æºñ´¢±â°úÇÐȸÁö ½É»çÀ§¿ø, ´ëÇѺñ´¢±â°úÇÐȸÁö ÆíÁýÀ§¿ø, ´ëÇѳ²¼º°úÇÐȸ ÀÌ»ç¿Í ¿¬±¸À§¿øÀ¸·Î Ȱµ¿ ÁßÀÌ´Ù.